Abstract: The increasing prevalence of mobile devices among patients of all demographic groups has the potential to transform the ways we diagnose, monitor, treat, and study mental illness. As new tools and technologies emerge, clinicians and researchers are confronted with an increasing array of options both for clinical assessment, through digital capture of the essential behavioral elements of a condition, and for intervention, through formalized treatments, coaching, and other technology-assisted means of patient communication. And yet, as with any new set of tools for the assessment or treatment of a medical condition, establishing and adhering to reporting guidelines-that is, what works and under what conditions-is an essential component of the translational research process. Here, using the recently published World Health Organization mHealth Evaluation, Reporting and Assessment guidelines for evaluating mobile health applications, we review the methodological strengths and weaknesses of existing studies on smartphones and wearables for schizophrenia. While growing evidence supports the feasibility of using mobile tools in severe mental illness, most studies to date failed to adequately report accessibility, interoperability, costs, scalability, replicability, data security, usability testing, or compliance with national guidelines or regulatory statutes. Future research efforts addressing these specific gaps in the literature will help to advance our understanding and to realize the clinical potential of these new tools of psychiatry.
INTRODUCTION
Few would dispute the unmet need in mental health services for individuals with severe mental illness, in terms of both access to services and ability to provide high-quality services at the point of care. 1 Research into the genetic and neural mechanisms of schizophrenia has yielded important breakthroughs, but these discoveries have yet to transform care for patients. Duration of untreated psychosis ranges from many months to many years, 2 reflecting the formidable challenge faced in screening for serious mental illness. Once treatment is initiated, patients' most pressing illness concerns, such as getting back to work or school (i.e., function) and gaining an understanding of how their symptoms are likely to evolve over time with and without intervention (i.e., prognosis), are often not fully addressed. Antipsychotic medications, viewed as a panacea for schizophrenia when first developed in the 1950s, are largely ineffective for many of its symptoms, including cognitive and negative symptoms, 3 and are often accompanied by adverse effects that can carry significant lifelong morbidity. Patients and providers are understandably eager for innovative approaches to address any of these challenges-which might improve access or outcomes for individuals with severe mental illness. 4 Mobile and connected technologies are a prominent example of such an approach. They offer tremendous opportunities to address some of the real-world difficulties in working with individuals with schizophrenia and other severe mental illnesses. As detailed below, increased ownership of smartphones, coupled with increasingly sophisticated sensor and communication technologies, has created new opportunities for innovation. And yet, as the field seeks to understand and validate these tools, considerable challenges remain in both the implementation and potential uses (and misuses), which must be thoroughly vetted, as with any new proposed tool or treatment modality. Here we aim to present a balanced view of both the opportunities and the challenges in the field of mobile-health and smartphone-application studies for schizophrenia, with particular attention to the strengths and weaknesses as described in currently published accounts of mobile applications. While the scope of the present review was limited to the mobile-health application literature in schizophrenia, we anticipate that the insights gleaned from our focused study will extend to other areas of psychiatry in which similar technology-based solutions are being applied and tested.
Increased Smartphone Access
While barriers still exist, smartphone use among patients with serious mental illness is rising. 5 To be sure, socioeconomic factors such as education, income, and cultural norms likely keep modern technologies out of reach for many individuals. 6 The idea of a "digital divide" seems to be rapidly closing, however, with recent evidence suggesting that individuals with schizophrenia now own smartphones at rates closer to the general population than ever before. 6, 7 A National Alliance of Mental Illness study from 2014 also surveyed those with schizophrenia and found that in a sample of 451 patients, 54% had access to a smartphone. 8 Younger patients, especially those with first-episode schizophrenia, seem especially interested in using digital technologies like smartphones as part of their care. 9, 10 Data from the 2014 study also suggested that patients may already be using their phones for therapeutic purposes, with 42% of respondents reporting that they often or very often listen to music or audio files on their devices to help manage or block voices. 8 
Advances in Device Capabilities
The increased ownership and interest in smartphones for care in schizophrenia parallel the increasing technical capabilities of these devices to track relevant features of psychiatric syndromes. Not only can smartphones capture patients' realtime symptoms via surveys and other brief interactions, but they can also be harnessed to collect more-objective social and behavioral measurements. Current and in-progress studies are collecting data from smartphone sensors to shed light on how patients with schizophrenia experience the illness.
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Smartphones can collect what is known as "active data" such as symptom surveys or voice-recording samples that the patient agrees to provide. Real-time symptom surveys delivered on the phone have the potential to minimize recall bias and to provide more accurate reporting, and voice data-the subject of ongoing research projects-have been shown to be a predictor of conversion to schizophrenia. 12 But smartphone platforms can also capture "passive data," which is collected without the active involvement of the patient. For example, utilizing global positioning system data from phones, it is possible to learn about the mobility traces of patients and how active they are outside of the clinic or hospital. Recording anonymized call and text logs can provide data on how social and engaged patients may be. Wearable sensors and smart watches can now also collect physiological data, such as heart rate, galvanic skin conductance, and sleep patterns. The ability to collect large quantities of personal data from patients also raises ethical concerns, 13, 14 and it is therefore imperative that such data is used to help patients rather than to profile them. But the ability to collect such data also raises hopes that, when combined with careful analysis and appropriate statistical methods, the data may reveal new markers, patterns, and views of schizophrenia and other mental illnesses via novel "digital phenotypes." 11, 15 Mobile Intervention In addition to monitoring symptoms, smartphones have the potential to offer adjunctive therapies and treatments for patients with both mild and severe forms of mental illness. On the milder side of the illness spectrum, app-based interventions could provide self-management tools that meet the patient's need without engaging a costly health care infrastructure, much like "diet and exercise" have become the first-line therapy for many cardiometabolic conditions when confronted at a mild stage. Conversely, in severe illness, app-based adjunctive interventions could help patients with treatment adherence, between-visit check-ins, and other prompts designed to promote positive behavioral change.
Research has shown that patients with schizophrenia find text-message reminders about medication adherence delivered to their phones useful and easy to use. 16 Therapies like cognitive-behavioral therapy (CBT) are increasingly being shown effective in schizophrenia, with high acceptability among patients and small to medium between-group effects for psychotic symptoms, 17 and a growing research literature is investigating the ability of smartphones to deliver CBT. 18 While evidence for CBT on a smartphone for schizophrenia is limited, studies have demonstrated the ability of interventions delivered via the phone to increase motivational behaviors and the quality of life in patients with schizophrenia. 19 A systematic review of smartphones apps for schizophrenia published in 2015 noted overall high rates of feasibility and acceptability of use among patients, though efficacy remains to be determined. 20 A robust body of evidence is available regarding the use of computers to deliver cognitive remediation to patients with schizophrenia, with ongoing research to assess how smartphones can deliver such therapy to patients. 21 In addition, the large screens and increasingly faster data connections of smartphones make them practical platforms for telepsychiatry, thereby presenting the potential of easy-toaccess digital visits.
Evidence Is Lacking; Studies and Standards Needed Despite the potential and encouraging early study results, the impact of smartphones and apps to change psychiatric clinical care has yet to be realized. Neither psychiatric care nor schizophrenia treatment can be formulated as engineering problems that will be solved with a new technology alone. Any solutions or advances in these areas can come only through considering the myriad personal and social factors involved, careful clinical investigation of new interventions, and strong and reproducible science. While the number of clinical studies on smartphones and connected devices for schizophrenia care remains limited, 20 there has been no investigation to date on the methods and reporting of mobile health (mHealth) studies for schizophrenia.
At this early stage, because of the ever increasing number (and capabilities) of mental health apps and the wide range of potential clinical targets, examining the methods and reporting of mHealth studies in schizophrenia is perhaps of greater value than understanding app-based studies solely in terms of their individual outcomes. Understanding the quality, completeness, and objectivity 22 of studies is important when considering and evaluating their results. Furthermore, comparing existing research methodologies in a standardized manner can highlight broad gaps in study methods-which can advance research conduct for future studies. Encouraging better methodologies and thorough reporting of methods and results will, in turn, lead to better knowledge of how these technologies can be used for clinical care.
Just as smartphones and apps are relatively new technologies, standards for reporting the results of clinical studies on these technologies are also new. In early 2016, the World Health Organization (WHO) released the mHealth Evidence and Assessment (mERA) checklist. The checklist offers 16 criteria developed by expert consensus and field trials to define the minimum information necessary to understand the content, context, technical features, and reproducibility of mHealth studies. It is important to note that the "checklist does not aim to support the design or implementation of such studies, or to evaluate the quality of the research methods used. Rather, it is intended to improve transparency in reporting, promote a critical assessment of mHealth research evidence, and help improve the rigor of future reporting of research findings." 22 While the mERA checklist has not, as of this writing, been well validated or widely used, it provides a useful framework for discussing mobile health researchin particular, by ensuring that many disparate aspects of research methodology are covered. While not specific to psychiatry or schizophrenia research, the mERA framework serves as a tool for evaluating the existing literature and as a guide for standardizing how clinical studies for smartphone interventions are reported.
METHODS
The aim of this systematic review is to identify all existing studies of smartphone interventions for schizophrenia and to evaluate their methodology and reporting against preestablished criteria for app-based studies in psychiatric research. We chose to study schizophrenia for three reasons: it is a clinically important topic; research on this condition is representative of the state of mobile psychiatry efforts; and the literature is well-defined because of widespread agreement regarding the definition and treatment of schizophrenia (versus mood disorders, a much more broad and diverse category).
We conducted a literature review searching for all studies utilizing smartphones in the care of patients with schizophrenia. Our article builds upon, and follows up, the research of a prior review article on smartphones and fitness trackers for schizophrenia. Details of the search criteria can be found in that earlier study. 17 Our search extended the previous one by approximately a year-from May 24, 2015, to July 24, 2016 . This extended search identified three new studies in addition to the eight studies previously identified. A copy of the mERA checklist is shown in Table 1 . 22 For each of the 11 studies, three of the authors (JT, JF, and NM) independently applied the 16-item mERA checklist and noted whether each item on the checklist was met, in a binary manner, by that study.
RESULTS
Cohen's kappa was used to assess inter-rater reliability between the three sets of ratings. A strong agreement between raters was found (kappa = .64). The discrepancy in ratings occurred mainly on two criteria: technology platform (six differences in rating), and usability/content testing (five differences in rating). These differences were most likely due to differing opinions of the amount of detail required to satisfy each criterion. The number of studies that met each criterion, after consensus was reached between raters, is displayed in Figure 1 .
Of the 11 studies identified though our search, [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] none provided a cost assessment of the technology used in the study. Only Macias and colleagues 30 met the criterion "compliance with national guidelines or regulatory status," by indicating that their application "supports two-way HIPAA compliant messaging," and only Forchuk and colleagues 33 mentioned the ways that the mobile technology interacted and integrated with the current health information systems used in the population studied, thus satisfying the criterion for "interoperability/health information systems."
Ainsworth and colleagues 25 and Naslund and colleagues 32 both met the criterion for "limitations for delivery at scale." The authors reflected on potential stumbling blocks for adopting the technology in real-word situations. For example, Ainsworth and colleagues 25 noted, "As this technology makes the transition from research to real-world clinical application, it will be vital to assess the feasibility and uptake of this software over longer periods of time and factors influencing non-participation and withdrawal"-thereby acknowledging the potential barriers to translating an intervention that is successful in a research study into an intervention suitable for wider use. Ainsworth and colleagues 25 list specific potential solutions for the scalability of interventions, including "machine learning in order to tailor the choice of questions," "person-tailored sampling," and "automated and clinician-delivered feedback."
Five studies [25] [26] [27] 30, 31 reported data on the methods of "data security" used on their technology platforms, including the methods used to protect the privacy of the study Clearly presents the availability of infrastructure to support technology operations in the study location. This refers to physical infrastructure such as electricity, access to power, connectivity, etc. in the local context. Reporting X% network coverage rate in the country is insufficient if the study is not being conducted at the country-level.
Technology platform 2 Describes and provides justification for the technology architecture. This includes a description of software and hardware and details of any modifications made to publicly available software.
Interoperability/health information systems (HIS) context 3 Describes how mHealth intervention can integrate into existing health information systems. Refers to whether the potential of technical and structural integration into existing HIS or program has been described, irrespective of whether such integration has been achieved by the existing system.
Intervention delivery 4
The delivery of the mHealth intervention is clearly described. This should include frequency of mobile communication, mode of delivery of intervention (that is, SMS, face-to-face, interactive voice response), and timing and duration of delivery.
Intervention content 5 Details of the content of the intervention are described. Source and any modifications of the intervention content are described.
Usability/content testing 6 Describe formative research and/or content and/or usability testing with target group(s) clearly identified, as appropriate.
User feedback 7
Describes user feedback about the intervention or user satisfaction with the intervention. User feedback could include user opinions about content or user interface, their perceptions about usability, access, connectivity, etc.
Access of individual participants 8
Mentions barriers or facilitators to the adoption of the intervention among study participants. Relates to individual-level structural, economic, and social barriers or facilitators to access such as affordability, and other factors that may limit a user's ability to adopt the intervention.
Cost assessment 9
Presents basic cost assessment of the mHealth intervention from varying perspectives. This criterion broadly refers to the reporting of some cost considerations for the mHealth intervention in lieu of a full economic analysis. If a formal economic evaluation has been undertaken, it should be mentioned with appropriate references. Separate reporting criteria are available to guide economic reporting.
Adoption inputs/programme entry 10 Describes how people are informed about the program, including training, if relevant. Includes description of promotional activities and/or training required to implement the mHealth solution among the user population of interest.
Limitations for delivery at scale 11 Clearly presents mHealth solution limitations for delivery at scale.
Contextual adaptability 12
Describes the adaptation, or not, of the solution to a different language, population, or context. Any tailoring or modification of the intervention that resulted from pilot testing/usability assessment is described.
Replicability

13
Detailed intervention to support replicability. Clearly presents the source code/screenshots/flowcharts of the algorithms or examples of messages to support replicability of the mHealth solution in another setting.
Data security 14
Describes the data-security procedures/confidentiality protocols Continued on next page
Mobile Health and Smartphone Application Studies for Schizophrenia participants. Seven studies [23] [24] [25] [26] [27] [28] 32 described the study procedure in sufficient detail to meet the "reliability" criterion. Similarly, nine studies [23] [24] [25] [26] [27] [28] [29] 32, 33 described the "technology platform" in sufficient detail to satisfy that criterion. Eight 24-27,30-33 of the 11 studies mentioned using the population of interest in developing the content of the intervention. While the purpose of many of the studies reviewed was to assess both the usability of the technology and the content of the proposed intervention, Ben-Zeev and colleagues 27 were particularly proactive in including the study population in every stage of developing their mobile application; before beginning their pilot study of the app in the community, they worked with "patients and clinicians and community settings" to develop their app and then tested the app "with individuals with schizophrenia in laboratory conditions." Most studies that met this criterion did not provide that much detail; instead, they usually provided data on the feedback participants had given over the course of the study.
DISCUSSION
Our results suggest areas of both strength and weakness in the current reporting of clinical studies of smartphone apps for schizophrenia. The studies differed substantially in the technologies used and in the sizes and characteristics of their cohorts. Nonetheless, several trends emerged with respect to the elements of the mERA checklist that were missing from the studies. Fewer than 10 of the 11 studies met the reporting mERA criteria for the following categories: accessibility of technology platforms, interoperability/health information systems, cost assessment, limitations of delivery at scale, replicability, data security, usability testing, and compliance with national guidelines or regulatory statutes. These categories are explored in greater detail below. Understanding the current limitations of each of these areas is important in guiding future research on smartphones for schizophrenia. Additionally, it is important to consider that these same limitations may equally apply for technology research on many 
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Mechanism used to assure that content or other guidance/information provided by the intervention is in alignment with existing national/ regulatory guidelines and is described.
Fidelity of the intervention
16
Was the intervention delivered as planned? Describe the strategies employed to assess the fidelity of the intervention. This may include assessment of participant engagement, use of back-end data to track message delivery, and other technological challenges in the delivery of the intervention.
Adapted from Agarwal S et al. (2016). 22 Reproduced with permission from the authors and the World Health Organization.
other psychiatric conditions, such as major depressive and bipolar disorders.
Technology Platforms Should Be Accessible
In order to understand the impact of a mobile health study, it is important to understand the technology behind that study. The mERA checklist notes that links to any code used to support the technology should be publicly available, hardware choices described in detail, and other information provided to allow others to replicate the study. No studies reviewed made code publicly available, but the explanation may be that none of the studies was designed as an open source or public platform. Only 2 of the 11 studies used commercial devices; 28, 32 all other studies used customized apps or devices. While it may be possible to come close to approximating and recreating the smartphone apps used in early schizophrenia studies, 23, 25 the technology platforms in more recent studies are more complex because of the numerous interactive and passive data features. 27, 30 This situation raises a challenge for mobile health research. As apps become more complex, understanding the technology platform behind them and recreating similar versions-by other groups wishing to reproduce studies-may be nearly impossible. For research to advance, groups will need to make access to their platforms available to others and provide access to code used to create the platforms.
Technology Platforms Should Support Interoperability
Despite the potential of mobile health technologies to improve care, it is also possible that they can disrupt care through fragmenting information or creating unsupported care pathways that are detached from established health systems. The importance of interoperability of mobile health technologies was recently underscored by a report from the Office of the National Coordinator for Health Information Technology, which called for better integration of smartphone apps and wearables with medical record systems. 34 Of note, only one of the studies reviewed here discussed interoperability, 33 although the lack of reporting on this topic can be explained, in part, by the studies' pilot character. Going forward, studies should at least discuss strategies for clinical integration and what such integration might accomplish. With new data-sharing standards like Substitutable Medical Applications, Reusable Technologies (SMART) and Fast Health Interoperability Resources (FHIR), 35 interoperability is becoming technically easier, and future studies may have the opportunity of integrating mobile data into the medical record system. At the present time, however, barriers remain.
Technology Platforms Should Report on Cost Assessment
While cost assessments are often omitted from clinical research, reporting data on the financial implications of mobile health interventions is important for future studies. With the mERA framework, reporting the costs of technological interventions can help in comparing alternatives and is critical for evaluating the cost-effectiveness of their implementation. If it can be shown that particular mobile health interventions would enhance the efficacy and efficiency of existing care systems, clinics and hospital systems would be more likely to adopt them. Especially for disorders like schizophrenia, where funding is already limited, it will be important for smartphone apps to demonstrate evidence of cost-effectiveness in advance if those apps are to be widely adopted. Although none of the 11 eligible studies reported on cost assessment, it should be kept in mind that these studies were small in scale. Thus, cost assessment will be more informative and important in future, larger-scale studies-and also necessary for the translation of research findings into clinical practice.
Technology Platforms Should Discuss Their Scalability
By their nature as pilot studies, the studies in the current research base for mobile health interventions for schizophrenia focus more on feasibility than scalability. Information is lacking, however, on how such interventions could be utilized on a regional or population-level scale. Only 2 of the 11 studies discussed limitations regarding delivery on a broad scale. 25, 32 Outside of schizophrenia research, one recent study examined how a mobile-app intervention for alcoholism could be scaled up from a single clinical study 36 to regional clinics. The study noted that the app faced numerous barriers in scaling up; only 15% of the original clinics still used it at two years. 37 The potential of smartphone interventions to address populationlevel unmet needs, along with their potential to provide remote support to those who cannot physically access clinical services, has been driving the interest in using this technology for schizophrenia. The feasibility and benefits of using such interventions for those purposes has yet to be evaluated. Smartphones app need to show that they can be scalable beyond a single clinical study.
Technology Platforms Studies Should Be Replicable
The essence of any scientific advance and clinical intervention rests upon replicability. While none of the 11 studies we reviewed has been reproduced, we noted that 7 of the 11 would be possible to replicate based on the mERA guidelines. The 7 that seem replicable [23] [24] [25] [26] [27] [28] 32 -the 4 earliest studies, [23] [24] [25] [26] the FOCUS study, 27 and the 2 studies of a fitness tracker 28, 32 involved the assessment of individual scales, modules, or "out-of-the-box" devices used for schizophrenia patients. As apps for smartphones become more complex and as smartphone interventions continue to utilize more sensors, features, and modules, it will become more difficult to replicate app studies. While the mERA does not focus on replicability of data analysis and statistical methods, this consideration is also an important one, given that an app platform collecting data is only as useful as the methods to process those data. Thus, there is a growing need to establish standards for the field, which would help ensure that app studies can be replicated.
Technology Platforms Should Provide Appropriate Data Security
While smartphone apps are not often thought of as devices that can cause harm, data security is one area where these tools create risk. If apps are created and implemented without adequate data-security standards, then private patient health information is vulnerable to public disclosure, and trust in these tools will be quickly lost. Vulnerabilities in data security were the main reason why, in October 2015, the United Kingdom's National Health Service closed its app library, 38 which had offered various smartphone apps, many directed at psychiatric conditions. Lack of appropriate data security will also make it impossible to implement apps in clinical care, as such security is often mandated by national and local laws and regulations. While it can be easy to design an app that collects patient data, designing one that meets complex, demanding security requirements (such as the United States' Health Insurance Portability and Accountability Act) presents a challenge for apps aiming to improve clinical care. Thus, research articles must report on their apps' data security or otherwise explain how their results should be interpreted if their platforms lack such security. The fact that only 4 of the 11 studies reported on data security suggests that this area stands much in need of improvement.
Technology Platforms Should Be in Compliance with National Guidelines and Regulatory Statutes Any smartphone app or technology platform will be most useful if it can actually be used in clinical situations and toward patient care. Only 1 30 of the 11 studies reviewed discussed how its technology complied with regulatory statutes. Although the regulations for apps are complex and often change, it remains important to understand clinical app research in relation to the actual context within which the apps will ultimately be required to function. And without knowledge of how smartphone apps actually function under the real-world conditions of various national guidelines and regulatory statutes, it will be difficult to assess how smartphone apps can actually offer benefit or harm in practice. Recently, the Food and Drug Administration created a new website offering app developers an easy-to-use tool to learn which regulations may apply to their software. Researchers can also use this tool to determine which regulations would need to be considered when implementing their apps in clinical care.
Technology Platforms Should Conduct Usability Testing
For mobile health interventions to be successful, they need to be valued and used by patients. Although usability was a focus of the majority of the 11 studies we reviewed, in only one 27 were patients highly involved in developing the mobile technology. That same study also showed high levels of acceptability and potential effectiveness. Ensuring that patients are involved early on-not only in the testing of applications but also in their development-is important from both ethical and clinical-outcomes perspectives.
Additional Considerations
Though not exhaustive in scope, the WHO mERA criteria are a useful tool for evaluating mobile health studies. Other important areas to consider, especially for schizophrenia research, include incentives for user engagement as well as various questions concerning clinician contact. Across numerous smartphone studies, engagement and use of the apps have been shown to decrease with time. 18, 39, 40 While numerous factors may cause a user to engage less with any particular health app, 41 why this occurs in schizophrenia is unknown. Another question concerns the compensation of participants in smartphone clinical studies. As with mERA scalability, it is important to understand whether participants used the app simply because they were paid to do so or whether they found the app intrinsically useful. Questions concerning compensation are often unclear since participants may be offered new smartphones or wearable sensors for participating in studies, and the monetary value of such devices, though often large, may not be reported. Finally, another measure that would be useful is the time that study staff and clinician spend with participants. An app may be useful because it facilities more clinical visits and encourages people to use more health care services, or it may be useful because it offers a valuable service apart from connecting users with direct care. Though both are potentially useful contributions, they are different in their means of action. Data on how much time participants in app studies spend with clinicians and staff would thus offer useful data for understanding how an app actually operated under test conditions. While these data are not sufficient to explain the complexities of apps' mechanisms of action, an understanding of those mechanisms would be helpful in beginning to learn how the apps work and what staff resources are necessary to support them if implemented in clinical care. Of course, since the mERA (or any other scale for that matter) can evaluate only what is reported in the literature, it is possible that individual journals' limitations on words or pages may, in effect, bias reporting or otherwise affect what is included in particular articles. Researchers should therefore consider adding supplementary online materials that most journals allow in order to provide full and comprehensive reporting of study methodology.
While the mERA checklist offers a useful tool to guide a discussion about mobile health research, it is only a single scale and not yet well validated. It does not have the influence and weight of, for example, the CONSORT guidelines that have become an essential tool in the funding and publication of clinical trials. Additionally, the mERA is structured to offer equal weight to each criterion even though the relevance of particular criteria may depend on the study in question. For example, if a study is not replicable, cost-effectiveness and scalability may become irrelevant. Despite these limitations, our findings that study methodologies are especially lacking with regard to compliance with national guidelines, replicability, scalability, cost assessment, and interoperability were clear and consistent, and likely would persist even if we had used a different rating tool to assess the literature.
Given that the majority of articles we examined were reporting pilot studies, it is interesting to consider whether it would be useful to have a more specialized evaluation tool for early-stage studies. That question aside, the mERA in its current form offers useful data even for pilot studies; the results of this review have suggested gaps in the literature that new pilot studies need to explore. The mERA also does not take into account disease-specific considerations (such as decision-making capacity in schizophrenia), which could improve the utility of future evaluation strategies. Finally, while our focus on schizophrenia studies makes it difficult to generalize to other areas of psychiatry, none of the available evidence suggests that mobile applications targeting schizophrenia and other forms of severe mental illness should be evaluated using different criteria from tools designed for other disorders, such as depression or bipolar disorder. Thus, we anticipate that our findings and recommendations will remain relevant and applicable across many areas of psychiatry.
CONCLUSIONS
Technology for psychiatry and schizophrenia is rapidly changing. While smartphone apps are at the forefront of research at the time of this writing (mid 2016), we anticipate that other technologies, such as wearables and virtual or augmented reality, will attract similar levels of attention, hope, and speculation in the years to come, as the field continues to seek out innovative solutions to the complex challenges inherent to managing mental illness. In each case, whether or not to adopt new technologies in particular treatment settings should depend on a rigorous evaluation for clinical effectiveness and should also take into account the many other factors (e.g., data privacy, usability, cost) that would likely govern their use in real-world settings. While further refinements are to be expected, the WHO mERA guidelines provide a useful tool for this type of comprehensive assessment of mobile health research methodologies in the evolving landscape of digital health.
Finally, although the literature on schizophrenia and smartphones is still in its early stages, a systematic examination using established criteria nonetheless helps to identify not only areas of promise in addressing the many known clinical challenges but also the gaps where further research or better reporting is needed. The criteria reflected in the WHO mERA guidelines can help to ensure that the most promising technical solutions are developed in a manner that remains consistent with both core treatment principles and realworld constraints. By focusing our collective resources and research agendas on solutions that work both in principle and in practice, we as a field can dramatically increase the potential of these new technologies to improve both access and outcomes even in the most severe forms of mental illness.
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